This site is intended for health professionals only

Erlotinib in pancreatic cancer

teaser

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

Roche has received regulatory approval from the EMEA for erlotinib (Tarceva) for the treatment of patients with metastatic pancreatic cancer, in combination with gemcitabine.

Approval was based on data from the PA3 phase III study, which showed that for patients with metastatic disease, treatment with erlotinib plus gemcitabine results in a statistically significant survival compared with gemcitabine alone.






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x